PMID- 31698409 OWN - NLM STAT- MEDLINE DCOM- 20201228 LR - 20231113 IS - 1740-634X (Electronic) IS - 0893-133X (Print) IS - 0893-133X (Linking) VI - 45 IP - 3 DP - 2020 Feb TI - Blocking CRH receptors in adults mitigates age-related memory impairments provoked by early-life adversity. PG - 515-523 LID - 10.1038/s41386-019-0562-x [doi] AB - In humans, early-life adversity is associated with impairments in learning and memory that may emerge later in life. In rodent models, early-life adversity directly impacts hippocampal neuron structure and connectivity with progressive deficits in long-term potentiation and spatial memory function. Previous work has demonstrated that augmented release and actions of the stress-activated neuropeptide, CRH, contribute to the deleterious effects of early-life adversity on hippocampal dendritic arborization, synapse number and memory-function. Early-life adversity increases hippocampal CRH expression, and blocking hippocampal CRH receptor type-1 (CRHR1) immediately following early-life adversity prevented the consequent memory and LTP defects. Here, we tested if blocking CRHR1 in young adults ameliorates early-life adversity-provoked memory deficits later in life. A weeklong course of a CRHR1 antagonist in 2-month-old male rats prevented early-life adversity-induced deficits in object recognition memory that emerged by 12 months of age. Surprisingly, whereas the intervention did not mitigate early-life adversity-induced spatial memory losses at 4 and 8 months, it restored hippocampus-dependent location memory in 12-month-old rats that experienced early-life adversity. Neither early-life adversity nor CRHR1 blockade in the adult influenced anxiety- or depression-related behaviors. Altogether, these findings suggest that cognitive deficits attributable to adversity during early-life-sensitive periods are at least partially amenable to interventions later in life. FAU - Short, Annabel K AU - Short AK AUID- ORCID: 0000-0001-9654-3197 AD - Department of Anatomy and Neurobiology, University of California- Irvine, Irvine, CA, USA. akshort@uci.edu. AD - Department of Pediatrics, University of California-Irvine, Irvine, CA, USA. akshort@uci.edu. FAU - Maras, Pamela M AU - Maras PM AD - Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, USA. FAU - Pham, Aidan L AU - Pham AL AD - Department of Anatomy and Neurobiology, University of California- Irvine, Irvine, CA, USA. AD - Department of Pediatrics, University of California-Irvine, Irvine, CA, USA. FAU - Ivy, Autumn S AU - Ivy AS AUID- ORCID: 0000-0003-1775-6253 AD - Department of Anatomy and Neurobiology, University of California- Irvine, Irvine, CA, USA. AD - Department of Pediatrics, University of California-Irvine, Irvine, CA, USA. FAU - Baram, Tallie Z AU - Baram TZ AUID- ORCID: 0000-0003-0771-8616 AD - Department of Anatomy and Neurobiology, University of California- Irvine, Irvine, CA, USA. AD - Department of Pediatrics, University of California-Irvine, Irvine, CA, USA. AD - Department of Neurology, University of California-Irvine, Irvine, CA, USA. LA - eng GR - R01 MH073136/MH/NIMH NIH HHS/United States GR - R01 NS028912/NS/NINDS NIH HHS/United States GR - P50 MH096889/MH/NIMH NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20191107 PL - England TA - Neuropsychopharmacology JT - Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology JID - 8904907 RN - 0 (Pyrimidines) RN - 0 (R 121919) RN - 0 (Receptors, Corticotropin-Releasing Hormone) RN - 5CLY6W2H1M (CRF receptor type 1) SB - IM MH - Age Factors MH - Aging/drug effects/physiology/*psychology MH - Animals MH - Animals, Newborn MH - Female MH - Injections, Intraventricular MH - Male MH - Memory Disorders/etiology/*prevention & control/*psychology MH - Pregnancy MH - Pyrimidines/administration & dosage MH - Random Allocation MH - Rats MH - Rats, Sprague-Dawley MH - Receptors, Corticotropin-Releasing Hormone/*antagonists & inhibitors/physiology MH - Stress, Psychological/complications/*drug therapy/*psychology PMC - PMC6969076 EDAT- 2019/11/08 06:00 MHDA- 2020/12/29 06:00 PMCR- 2021/02/01 CRDT- 2019/11/08 06:00 PHST- 2019/08/21 00:00 [received] PHST- 2019/10/28 00:00 [accepted] PHST- 2019/10/26 00:00 [revised] PHST- 2019/11/08 06:00 [pubmed] PHST- 2020/12/29 06:00 [medline] PHST- 2019/11/08 06:00 [entrez] PHST- 2021/02/01 00:00 [pmc-release] AID - 10.1038/s41386-019-0562-x [pii] AID - 562 [pii] AID - 10.1038/s41386-019-0562-x [doi] PST - ppublish SO - Neuropsychopharmacology. 2020 Feb;45(3):515-523. doi: 10.1038/s41386-019-0562-x. Epub 2019 Nov 7.